Serotonergic agents and Parkinson's disease
- 30 September 2004
- journal article
- review article
- Published by Elsevier in Drug Discovery Today: Therapeutic Strategies
- Vol. 1 (1) , 35-41
- https://doi.org/10.1016/j.ddstr.2004.08.002
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Sarizotan, a serotonin 5-HT 1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profileJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2004
- Contribution of the serotonin 5-HT1A receptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in ratsNeuropharmacology, 2003
- Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian modelsNeurology, 2001
- Autoradiographic mapping of 5-HT1B and 5-HT1D receptors in the post mortem human brain using [3H]GR 125743Brain Research, 2001
- Role of 5-HT2C receptors in the control of central dopamine functionTrends in Pharmacological Sciences, 2001
- A review of central 5-HT receptors and their functionPublished by Elsevier ,1999
- Quantitative and morphometric data indicate precise cellular interactions between serotonin terminals and postsynaptic targets in rat substantia nigraNeuroscience, 1997
- Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neuronsBrain Research, 1987
- Supersensitivity of nigral serotonin receptors and rat rotational behaviourEuropean Journal of Pharmacology, 1981
- An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the ratJournal of Comparative Neurology, 1978